SCHEMBL16005357

SCHEMBL16005357

CC(C)(Cc1ccc2ccccc2c1)OC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
MMP1 P03956 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
CYP2A6 P11509 1/20 0.44
CASR P41180 7/20 0.44
CYP2D6 P10635 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KCNH2 Q12809 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
SLC13A5 Q86YT5 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16005355 0.89 MMP1 (0.46) CYP1A2MMP1MMP9MMP13CYP2A6
SCHEMBL1003605 0.81 CTSK (0.49) CYP1A2CYP2D6SLC6A2CTSKPPARG
SCHEMBL4610682 0.79 CYP1A2 (0.50) CYP1A2MMP1MMP9MMP13CYP2A6
SCHEMBL20067118 0.79 CYP1A2 (0.50) CYP1A2MMP1MMP9MMP13CYP2A6
SCHEMBL19341333 0.77 CYP2A6 (0.59) CYP1A2CYP2A6CASRHTR2AHTR2C
SCHEMBL29982408 0.76 CYP1A2 (0.62) CYP1A2MMP1MMP9MMP13CYP2A6
SCHEMBL8939501 0.76 CYP1A2 (0.62) CYP1A2MMP1MMP9MMP13CYP2A6
SCHEMBL20347157 0.76 SLC13A5 (0.45) CYP1A2MMP1MMP9MMP13CYP2A6
Ammonia Solution, Strong SCHEMBL27962083 0.76 CYP2A6 (0.57) CYP1A2CYP2A6CASRHTR2AHTR2C
SCHEMBL8872531 0.75 CYP1A2 (0.53) CYP1A2CYP2A6SLC13A5SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2774923-B1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE UNIV NAGOYA NAT UNIV CORP (JP) 2016-05-18 EP disclosed
US-8993777-B2 Method for producing phenyl-substituted heterocyclic derivative NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2015-03-31 US disclosed
US-20140275549-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-09-18 US disclosed
EP-2774923-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE National University Corporation Nagoya University (JP) 2014-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275549-A1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE PAH, DDT, NISCH CYP1A2 15/4885MMP1 4533/4885MMP9 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.